Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

Press/Media: Press / Media

PeriodOct 2 2018

Media coverage

1

Media coverage

  • TitleSafety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
    Media name/outletClinical Trials.gov
    CountryUnited States
    Date10/2/18
    PersonsAndrew Brenner